Synedica Cagri Reta Dual Injection Pen Kit – Retatrutide 40mg + Cagrilintide 4mg
Synedica Cagri Reta Dual Injection Pen Kit is a two-pen research kit combining Retatrutide 40mg and Cagrilintide 4mg for laboratory and scientific research applications. The Synedica catalogue identifies Pen 1 as Retatrutide 40mg and Pen 2 as Cagrilintide 4mg.
This research-focused kit is designed for researchers investigating peptide pharmacology, receptor activity, metabolic signalling and multi-pathway approaches involving incretin- and amylin-related mechanisms. It is supplied as research material and is not intended for human or veterinary use.
Synedica Cagri Reta Dual Injection Pen Kit Overview
| Specification | Details |
|---|---|
| Product | Synedica Cagri Reta Dual Injection Pen Kit |
| Pen 1 | Retatrutide 40mg |
| Pen 2 | Cagrilintide 4mg |
| Format | Dual 2-pen research kit |
| Category | Research Peptide / Metabolic Research |
| Intended use | Laboratory and scientific research only |
| Human use | Not for human use |
What Is the Synedica Cagri Reta Research Kit?
The Synedica Cagri Reta Dual Injection Pen Kit brings together two investigational peptide compounds in a convenient two-pen research format. Retatrutide is a multi-receptor agonist investigated for activity involving the GLP-1, GIP and glucagon receptors, while cagrilintide is an amylin-related peptide being investigated for metabolic and appetite-regulation pathways.
The combination provides researchers with an opportunity to study complementary signalling pathways in controlled laboratory research models. The two compounds remain supplied in separate pens, allowing each research material to be identified independently.
Retatrutide 40mg Research Pen
Retatrutide 40mg is the first component of the Cagri Reta kit. Retatrutide is a synthetic peptide being investigated as a triple agonist involving the GLP-1 receptor, GIP receptor and glucagon receptor.
Research into retatrutide has examined its effects on metabolic signalling, energy balance and body-weight regulation in experimental models. Its multi-receptor pharmacology makes it an important compound for researchers studying next-generation peptide approaches and metabolic pathways.
Cagrilintide 4mg Research Pen
Cagrilintide 4mg is the second component of the dual research kit. Cagrilintide is an amylin analogue investigated in research relating to appetite regulation, energy balance and metabolic signalling.
When studied alongside other metabolic research compounds, cagrilintide provides an additional pathway for investigating amylin-related biological activity and its interaction with other peptide signalling systems.
Cagri Reta Combination Research
The scientific interest surrounding the combination of cagrilintide and retatrutide has recently expanded. A Nature Metabolism study published in September 2026 investigated combined cagrilintide and retatrutide administration in diet-induced obese male rats. The researchers reported reductions in body weight and food intake alongside changes in metabolic markers in the experimental model.
Importantly, these findings are preclinical animal research and should not be interpreted as evidence of safety, efficacy or appropriate dosing in humans.
Researchers interested in the underlying science can review the published study in Nature Metabolism.
Research Applications
The Synedica Cagri Reta kit may be relevant to appropriately equipped research environments investigating:
- Peptide receptor pharmacology
- GLP-1 receptor signalling
- GIP receptor signalling
- Glucagon receptor pathways
- Amylin-related signalling
- Metabolic pathway research
- Energy-balance mechanisms
- Peptide combination research
- Experimental obesity and metabolic models
- Comparative peptide pharmacology
Research-Grade Peptide Kit Format
The two-pen format provides researchers with clearly separated research materials. The kit contains a 40mg Retatrutide research pen and a 4mg Cagrilintide research pen, making the individual components straightforward to identify during laboratory workflows.
Researchers should maintain appropriate laboratory documentation, follow their institutional protocols and use validated analytical procedures when evaluating peptide materials.
Storage and Handling
Research peptides should be handled according to the manufacturer’s product documentation and the requirements of the research laboratory. Storage conditions can vary depending on the formulation, packaging and stage of the research workflow.
- Keep research materials appropriately labelled.
- Follow the supplied storage documentation.
- Avoid unnecessary exposure to heat, light and environmental contamination.
- Use suitable laboratory handling procedures.
- Do not use research materials outside an appropriately controlled research environment.
Why Choose Synedica Cagri Reta?
The Synedica Cagri Reta Dual Injection Pen Kit provides researchers with two distinct peptide research materials in one organised kit. The combination of Retatrutide 40mg and Cagrilintide 4mg reflects growing scientific interest in investigating multiple metabolic signalling pathways together.
For researchers building a broader peptide research portfolio, explore the Synedica research peptide collection to view additional research products and available kits.
Important Research-Use Notice
For research use only. Synedica Cagri Reta is supplied as research material and is not intended for human or veterinary use. Retatrutide and cagrilintide are investigational compounds, and information presented on this page is provided for scientific and educational purposes only.
This product description does not provide medical advice, treatment recommendations or instructions for human administration. Researchers should use appropriate institutional procedures, laboratory controls and applicable safety protocols.
Frequently Asked Questions
What is Synedica Cagri Reta?
Synedica Cagri Reta is a dual research pen kit containing Retatrutide 40mg in Pen 1 and Cagrilintide 4mg in Pen 2.
How many pens are included?
The Synedica Cagri Reta product is supplied as a two-pen research kit: one Retatrutide pen and one Cagrilintide pen.
What is in Pen 1?
Pen 1 contains Retatrutide 40mg according to the current Synedica product catalogue.
What is in Pen 2?
Pen 2 contains Cagrilintide 4mg according to the current Synedica product catalogue.
Is Cagri Reta approved for human use?
This product is presented as research material and is not intended for human or veterinary use. Research findings should not be interpreted as evidence that a particular research formulation is approved or suitable for human administration.
What is Retatrutide?
Retatrutide is an investigational peptide being studied for activity at GLP-1, GIP and glucagon receptors. It is of interest in research into metabolic signalling and energy regulation.
What is Cagrilintide?
Cagrilintide is an investigational amylin analogue studied in relation to appetite, energy balance and metabolic pathways.
Where can I find more Synedica research products?
You can browse the wider range through the Synedica research products collection.
Explore Synedica Research Products
Researchers looking for additional peptide and research-material options can explore the Synedica collection for products covering metabolic research, recovery research and other scientific applications.









Reviews
There are no reviews yet.